A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antagonist reinfarction Italian study (CRIS)

The American Journal of Cardiology
F RengoD Vitale

Abstract

A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effects of verapamil on total mortality, cardiac mortality, reinfarction, and angina after an acute myocardial infarction. All patients, aged 30 to 75 years, consecutively admitted for acute myocardial infarction between 1985 and 1987 to the participating centers, and without contraindications to verapamil or history of severe heart failure were enrolled. Seven to 21 days (mean 13.8) after myocardial infarction, 531 patients were randomized to verapamil retard 360 mg/day, and 542 patients to placebo. At baseline, the 2 groups of patients had similar characteristics. Mean age was 55.5 years and 91% were men. During a mean follow-up of 23.5 months, 5.5% of the patients died. No differences between verapamil and placebo were observed in total mortality (n = 30 and 29, respectively) and cardiac death (n = 21 and 22, respectively). The verapamil group had nonsignificant lower reinfarction rates (n = 39 vs 49). The number of patients developing angina was significantly less in the verapamil group (n = 100 vs 132, RR = 0.8, 95% confidence interval 0.5 to 0.9). There were no differences in discontinuation of therapy caused by adverse reactions...Continue Reading

References

Jan 30, 1987·The American Journal of Cardiology·W G NaylerW J Sturrock
Nov 11, 1989·BMJ : British Medical Journal·P H HeldC D Furberg
Jun 1, 1987·International Journal of Cardiology·W G Nayler
Mar 26, 1982·JAMA : the Journal of the American Medical Association
Oct 1, 1982·The American Journal of Cardiology·O ParodiA Maseri
Nov 1, 1995·Journal of the American Geriatrics Society·M PahorR J Havlik
Sep 25, 1995·Archives of Internal Medicine·R J GlynnC H Hennekens
Apr 24, 1995·Archives of Internal Medicine·T A ManolioW B Applegate

❮ Previous
Next ❯

Citations

Nov 28, 1996·The New England Journal of Medicine·C H HennekensJ E Buring
Nov 5, 1999·The New England Journal of Medicine·D R Abernethy, J B Schwartz
May 26, 1999·Current Problems in Cardiology·M FreherM Gheorgiade
Mar 16, 2001·Expert Opinion on Pharmacotherapy·A Prasad, G Reeder
Mar 16, 2001·Expert Opinion on Pharmacotherapy·J Widimský
May 14, 1999·Journal of the American Geriatrics Society·M W GillmanS B Soumerai
Feb 14, 2013·Current Opinion in Pharmacology·Rhonda M Cooper-DeHoffCarl J Pepine
Aug 1, 1997·American Heart Journal·F H Messerli, L Michalewicz
Oct 2, 2003·The Annals of Pharmacotherapy·Menno E van der ElstAnthonius de Boer
Nov 27, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Takahide KohroUNKNOWN JCAD Investigators
Mar 9, 1999·Journal of Cardiovascular Pharmacology·N FerraraF Rengo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.